Cancer combo study pulled before starting
NCT ID NCT06084689
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This study was planned to test two drugs, Ezabenlimab and BI 907828, in people with advanced solid tumors like sarcoma, lung, breast, colorectal, or bile duct cancer. The goal was to see if the combination could control tumor growth for at least 24 weeks. However, the study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Poitiers
Poitiers, France
-
Centre Eugène Marquis
Rennes, France
-
Centre Georges François Leclerc
Dijon, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, 59000, France
-
Institut Bergonié
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.